Methods and compositions to inhibit symptoms associated with veisalgia
Inventors
Iversen, Jacqueline M. • Iversen, James M.
Assignees
Interested in licensing this patent?
MTEC can help explore whether this patent might be available for licensing for your application.
Publication Number
US-10420756-B2
Publication Date
2019-09-24
Expiration Date
Abstract
The present invention relates to a method of reducing or preventing the symptoms associated with the intake of alcohol. The method comprises administering to a subject an effective amount of a pharmaceutical composition prior to alcohol intake. The pharmaceutical composition comprises a non-steroidal anti-inflammatory drug and a H1-antihistamine.
Core Innovation
The invention relates to preventing or reducing acute alcohol symptoms (veisalgia/hangover) by administering to a subject an effective amount of a pharmaceutical composition prior to alcohol intake. The pharmaceutical composition consists of a non-steroidal anti-inflammatory drug and an H1-antihistamine, optionally together with a pharmaceutical carrier or other pharmaceutically acceptable formulation components.
The pharmaceutical composition includes a non-steroidal anti-inflammatory drug selected from naproxen, a salt of naproxen, ibuprofen, and a salt of ibuprofen, and an H1-antihistamine selected from fexofenadine and cetirizine. The background and summary further describe an approach that combines NSAID activity with non-sedating H1 antihistamine activity to modulate thirst-related effects via ADH/vasopressin.
The disclosure emphasizes that symptoms associated with the intake of alcohol are inhibited when the NSAID and H1-antihistamine are combined and administered prior to alcohol intake. The summary indicates that the combined use provides unexpected synergy in inhibiting alcohol-associated symptoms such as headache, fatigue, and thirst/dry mouth, with described reductions relative to no-drug controls in example results.
Problem being solved: inhibiting acute alcohol symptoms (veisalgia/hangover) associated with alcohol intake by administering a pharmaceutical composition prior to alcohol intake. The disclosed solution targets alcohol-associated symptoms by combining an NSAID selected from naproxen or ibuprofen (including salts) with an H1-antihistamine selected from fexofenadine or cetirizine, optionally with pharmaceutically acceptable formulation components.
Claims Coverage
The partial content includes three independent claims (clm-00001, clm-00014, and clm-00015). Across these independent claims, the core inventive subject matter centers on administering a pre-alcohol composition that combines a specific NSAID family (naproxen/ibuprofen, or naproxen) with an H1-antihistamine (fexofenadine, and optionally cetirizine), optionally with standard formulation carriers/excipients; two of the independents further specify quantitative dosage ranges for naproxen sodium and fexofenadine and tighten the composition to particular actives.
Pre-alcohol administration of NSAID plus H1-antihistamine for symptom inhibition
A method of inhibiting the symptoms associated with intake of alcohol by administering to a subject an effective amount of a pharmaceutical composition prior to alcohol intake, wherein the pharmaceutical composition consists of (a) a non-steroidal anti-inflammatory drug selected from naproxen (or a salt of naproxen) and ibuprofen (or a salt of ibuprofen), (b) an H1-antihistamine selected from fexofenadine and cetirizine, and (c) optionally a pharmaceutical carrier and/or pharmaceutically acceptable formulation components, wherein the symptoms associated with the intake of alcohol are inhibited.
Specific naproxen sodium and fexofenadine amounts in pre-alcohol NSAID plus H1-antihistamine composition
A method of inhibiting the symptoms associated with intake of alcohol by administering to a subject an effective amount of a pharmaceutical composition prior to alcohol intake, wherein the pharmaceutical composition consists of about 220 mg to about 880 mg of naproxen sodium and about 60 mg to about 120 mg fexofenadine, with optionally a pharmaceutical carrier and/or pharmaceutically acceptable formulation components, wherein the symptoms associated with the intake of alcohol are inhibited.
Naproxen (or salt) plus fexofenadine composition for pre-alcohol symptom inhibition
A method of inhibiting the symptoms associated with intake of alcohol by administering to a subject an effective amount of a pharmaceutical composition prior to alcohol intake, wherein the pharmaceutical composition consists of naproxen and/or a salt thereof and fexofenadine, with optionally a pharmaceutical carrier and/or pharmaceutically acceptable formulation components, wherein the symptoms associated with the intake of alcohol are inhibited.
The independent claims collectively cover pre-alcohol inhibition of alcohol-associated symptoms using a pharmaceutical composition that combines an NSAID (naproxen/ibuprofen families, or naproxen specifically) with an H1-antihistamine (fexofenadine and/or cetirizine), optionally formulated with standard excipients/carriers; one independent further fixes naproxen sodium and fexofenadine to stated dosage ranges.
Stated Advantages
The symptoms associated with the intake of alcohol are inhibited.
Documented Applications
No documented applications found
Interested in licensing this patent?